Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation. A first tranche of ...

French pharmaceutical and healthcare company Sanofi on Friday announced a share buyback plan worth up to €2 billion ($2.08 ...

Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Execution of a share buyback agreement for up to €2 billionParis, February 7, 2025. On January 30, 2025, Sanofi announced its intention to ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 ( Sanofi ...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...